Hikal Ltd
HIKAL
Company Profile
Business description
Hikal Ltd manufactures chemical intermediates, specialty chemicals, active pharmaceutical ingredients, and contract research activities. Its products are distributed to the pharmaceutical, biotech, agrochemical, and specialty chemical industries. Its segments include Crop Protection and Pharmaceuticals. The majority of the revenue is derived from the pharmaceutical segment.
Contact
Great Eastern Chambers
6th Floor, Sector 11, CBD Belapur
Navi MumbaiMH400 614
INDT: +91 2262770299
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
3,595
Stocks News & Analysis
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
stocks
Undervalued ASX miner hits production homerun
Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.
stocks
Meta earnings: AI-driven improvements in top line fail to impress investors
We reiterate our fair value estimate for wide-moat Meta and view the after-market selloff as an overreaction
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.00 | 70.20 | -0.76% |
| CAC 40 | 8,515.81 | 30.17 | 0.36% |
| DAX 40 | 25,580.34 | 31.69 | -0.12% |
| Dow JONES (US) | 52,244.70 | 36.64 | 0.07% |
| FTSE 100 | 10,872.38 | 24.89 | -0.23% |
| HKSE | 25,884.43 | 25.55 | 0.10% |
| NASDAQ | 25,200.19 | 78.01 | 0.31% |
| Nikkei 225 | 64,362.02 | 2,494.59 | 4.03% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,443.34 | 5.71 | 0.08% |
| S&P/ASX 200 | 8,976.80 | 73.10 | -0.81% |
| SSE Composite Index | 3,832.26 | 27.57 | 0.72% |